| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Etienne Leveille, Owen A Ross, Ziv Gan-O. Tau and MAPT genetics in tauopathies and synucleinopathies. Parkinsonism & related disorders. vol 90. 2021-10-11. PMID:34593302. |
abnormal tau can also be observed in secondary tauopathies such as alzheimer's disease (ad) and synucleinopathies such as parkinson's disease (pd). |
2021-10-11 |
2023-08-13 |
Not clear |
| Etienne Leveille, Owen A Ross, Ziv Gan-O. Tau and MAPT genetics in tauopathies and synucleinopathies. Parkinsonism & related disorders. vol 90. 2021-10-11. PMID:34593302. |
understanding the role of mapt variations in tauopathies and synucleinopathies is therefore essential to elucidate the role of tau in the pathogenesis and phenotype of those disorders, and ultimately to develop targeted therapies. |
2021-10-11 |
2023-08-13 |
Not clear |
| Christos Proukaki. Somatic mutations in neurodegeneration: An update. Neurobiology of disease. vol 144. 2021-09-24. PMID:32712267. |
in common sporadic neurodegenerative disorders, relevant mutations have been reported in synucleinopathies, comprising somatic gains of snca in parkinson's disease and multiple system atrophy, and in alzheimer's disease, where a novel recombination mechanism leading to somatic variants of app, as well as an excess of somatic snvs affecting tau phosphorylation, have been reported. |
2021-09-24 |
2023-08-13 |
human |
| Tosha Williams, Zachary Sorrentino, Mary Weinrich, Benoit I Giasson, Paramita Chakrabart. Differential cross-seeding properties of tau and α-synuclein in mouse models of tauopathy and synucleinopathy. Brain communications. vol 2. issue 2. 2021-08-07. PMID:33094280. |
differential cross-seeding properties of tau and α-synuclein in mouse models of tauopathy and synucleinopathy. |
2021-08-07 |
2023-08-13 |
mouse |
| Tosha Williams, Zachary Sorrentino, Mary Weinrich, Benoit I Giasson, Paramita Chakrabart. Differential cross-seeding properties of tau and α-synuclein in mouse models of tauopathy and synucleinopathy. Brain communications. vol 2. issue 2. 2021-08-07. PMID:33094280. |
to understand the aetiology of such mixed pathologies, we investigated cross-seeding by human recombinant tau and human recombinant α-synuclein fibrillar species in a mouse model of tauopathy (line ps19) or synucleinopathy (line m20). |
2021-08-07 |
2023-08-13 |
mouse |
| Tosha Williams, Zachary Sorrentino, Mary Weinrich, Benoit I Giasson, Paramita Chakrabart. Differential cross-seeding properties of tau and α-synuclein in mouse models of tauopathy and synucleinopathy. Brain communications. vol 2. issue 2. 2021-08-07. PMID:33094280. |
thus, the tau + α-synuclein copolymer fibrils show robust transmission properties preferentially in rodent model of tauopathies but not in synucleinopathy, probably signifying an enhanced cooperative relationship between tau and α-synuclein in the tau seeding process. |
2021-08-07 |
2023-08-13 |
mouse |
| Lindsay E Stoyka, Casey L Mahoney, Drake R Thrasher, Drèson L Russell, Anna K Cook, Anner T Harris, Ashwin Narayanan, Tiara P Janado, David G Standaert, Erik D Roberson, Laura A Volpicelli-Dale. Templated α-Synuclein Inclusion Formation Is Independent of Endogenous Tau. eNeuro. vol 8. issue 3. 2021-07-02. PMID:33972291. |
reducing endogenous tau levels is protective in multiple models of alzheimer's disease (ad), tauopathies, and in some transgenic synucleinopathy mouse models. |
2021-07-02 |
2023-08-13 |
mouse |
| David J Irwin, Howard I Hurti. The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders. Journal of Alzheimer's disease & Parkinsonism. vol 8. issue 4. 2020-10-01. PMID:30473927. |
further, the co-occurrence of neocortical alpha-synuclein, tau and amyloid pathologies found at end-stage disease suggests a potential synergistic interaction of these individual pathologies in humans during life, mirroring experimental observations in animal and cell model systems that show how pathogenic species of synuclein fibrils can promote trans-synaptic spread of both tauopathy and synucleinopathy with strain-like properties. |
2020-10-01 |
2023-08-13 |
Not clear |
| Eftychia Vasili, Antonio Dominguez-Meijide, Tiago Fleming Outeir. Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved. Frontiers in molecular neuroscience. vol 12. 2020-10-01. PMID:31105524. |
the coexistence of asyn and tau aggregates suggests a strong overlap between tauopathies and synucleinopathies. |
2020-10-01 |
2023-08-13 |
Not clear |
| Elena Rodriguez-Vieitez, Henrietta M Nielse. Associations Between APOE Variants, Tau and α-Synuclein. Advances in experimental medicine and biology. vol 1184. 2020-04-08. PMID:32096038. |
while tau is a hallmark of alzheimer's disease (ad) and other non-ad tauopathies, and α-synuclein is the pathological feature of the spectrum of synucleinopathies including parkinson's disease (pd), parkinson's disease with dementia (pdd) and dementia with lewy bodies (dlb), the presence of co-pathologies is very frequent in all these diseases. |
2020-04-08 |
2023-08-13 |
human |
| Elena Rodriguez-Vieitez, Henrietta M Nielse. Associations Between APOE Variants, Tau and α-Synuclein. Advances in experimental medicine and biology. vol 1184. 2020-04-08. PMID:32096038. |
moreover, tau pet imaging studies comparing the patterns of tracer retention in synucleinopathies versus in other proteinopathies are scarce and much is still unknown regarding the relationships between apoe variants and fluid and/or imaging biomarkers of tau and α-syn. |
2020-04-08 |
2023-08-13 |
human |
| Diego Grassi, Natalia Diaz-Perez, Laura A Volpicelli-Daley, Corinne Ida Lasméza. Pα-syn* mitotoxicity is linked to MAPK activation and involves tau phosphorylation and aggregation at the mitochondria. Neurobiology of disease. vol 124. 2019-11-29. PMID:30472299. |
thus pα-syn* appears to be the trigger of a series of kinase mediated pathogenic events and a link between α-syn pathology and tau, another protein known to aggregate in parkinson's disease and other synucleinopathies. |
2019-11-29 |
2023-08-13 |
mouse |
| Alexis Fenyi, Audrey Coens, Tracy Bellande, Ronald Melki, Luc Bousse. Assessment of the efficacy of different procedures that remove and disassemble alpha-synuclein, tau and A-beta fibrils from laboratory material and surfaces. Scientific reports. vol 8. issue 1. 2019-11-20. PMID:30018327. |
α-synuclein fibrillar polymorphs, tau and aß 1-42 fibrillar assemblies have been shown to propagate, amplify and trigger the formation of protein deposits reminiscent of those present within the central nervous system of patients developing synucleinopathies, tauopathies and amyloid plaques after injection intracerebrally, intramuscularly, intraperitoneally or within the blood stream of model animals. |
2019-11-20 |
2023-08-13 |
Not clear |
| Reinis Svarcbahs, Ulrika Julku, Tommi Kilpeläinen, Mirva Kyyrö, Maria Jäntti, Timo T Myöhäne. New tricks of prolyl oligopeptidase inhibitors - A common drug therapy for several neurodegenerative diseases. Biochemical pharmacology. vol 161. 2019-10-23. PMID:30660495. |
moreover, prep co-localization with asyn, tau, and amyloid-beta hints to prep's possible role not only in the synucleinopathies but in other neurodegenerative diseases as well. |
2019-10-23 |
2023-08-13 |
Not clear |
| David J Irwin, Sharon X Xie, David Coughlin, Naomi Nevler, Rizwan S Akhtar, Corey T McMillan, Edward B Lee, David A Wolk, Daniel Weintraub, Alice Chen-Plotkin, John E Duda, Meredith Spindler, Andrew Siderowf, Howard I Hurtig, Leslie M Shaw, Murray Grossman, John Q Trojanowsk. CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology. vol 90. issue 12. 2019-07-30. PMID:29467305. |
csf tau and β-amyloid predict cerebral synucleinopathy in autopsied lewy body disorders. |
2019-07-30 |
2023-08-13 |
Not clear |
| John L Robinson, Edward B Lee, Sharon X Xie, Lior Rennert, EunRan Suh, Colin Bredenberg, Carrie Caswell, Vivianna M Van Deerlin, Ning Yan, Ahmed Yousef, Howard I Hurtig, Andrew Siderowf, Murray Grossman, Corey T McMillan, Bruce Miller, John E Duda, David J Irwin, David Wolk, Lauren Elman, Leo McCluskey, Alice Chen-Plotkin, Daniel Weintraub, Steven E Arnold, Johannes Brettschneider, Virginia M-Y Lee, John Q Trojanowsk. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain : a journal of neurology. vol 141. issue 7. 2019-07-17. PMID:29878075. |
our data imply that increased age and apoe ɛ4 status are risk factors for co-pathologies independent of neurodegenerative disease; that neurodegenerative disease severity influences co-pathology as evidenced by the prevalence of co-pathology in high alzheimer's disease and neocortical lewy body disease, but not intermediate alzheimer's disease or limbic lewy body disease; and that tau and α-synuclein strains may also modify co-pathologies since tauopathies and synucleinopathies had differing co-pathologies and burdens. |
2019-07-17 |
2023-08-13 |
Not clear |
| Kerstin Schweyer, Johannes Levin, Günter U Höglinge. [Current therapy studies in atypical Parkinson syndromes]. Fortschritte der Neurologie-Psychiatrie. vol 86. issue S 01. 2019-05-10. PMID:29996158. |
on the basis of the underlying pathology, namely the abnormal aggregation of the proteins alpha-synuclein or tau, atypical parkinson syndromes can be divided into synucleinopathies (multiple system atrophy, lewy body dementia) and tauopathies (progressive supranuclear palsy, corticobasal degeneration). |
2019-05-10 |
2023-08-13 |
Not clear |
| Julia E Gerson, Kathleen M Farmer, Natalie Henson, Diana L Castillo-Carranza, Mariana Carretero Murillo, Urmi Sengupta, Alan Barrett, Rakez Kaye. Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy. Molecular neurodegeneration. vol 13. issue 1. 2018-11-09. PMID:29544548. |
we have evaluated the efficacy of targeting the toxic, oligomeric form of tau protein by passive immunotherapy in a mouse model of synucleinopathy. |
2018-11-09 |
2023-08-13 |
mouse |
| Ronald Melk. How the shapes of seeds can influence pathology. Neurobiology of disease. vol 109. issue Pt B. 2018-07-26. PMID:28363800. |
here, a structural-molecular explanation based on the ability of proteins such as α-synuclein or tau to form assemblies that differ by their intrinsic architecture, stability, seeding capacity, and surfaces is proposed to account for distinct synucleinopathies and tauopathies. |
2018-07-26 |
2023-08-13 |
Not clear |
| Sarah Coakeley, Sang Soo Cho, Yuko Koshimori, Pablo Rusjan, Madeleine Harris, Christine Ghadery, Jinhee Kim, Anthony E Lang, Alan Wilson, Sylvain Houle, Antonio P Strafell. Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. vol 37. issue 9. 2017-09-19. PMID:28155586. |
while many parkinsonian disorders such as parkinson's disease, lewy body dementia, and multiple system atrophy are classified as synucleinopathies, progressive supranuclear palsy is coined a tauopathy due to the aggregation of pathological tau in the brain. |
2017-09-19 |
2023-08-13 |
Not clear |